Pelareorep + Retifanlimab
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anatomic Stage IV Breast Cancer AJCC v8
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
Trial Timeline
Jul 13, 2020 → Jun 30, 2025
NCT ID
NCT04445844About Pelareorep + Retifanlimab
Pelareorep + Retifanlimab is a phase 2 stage product being developed by Incyte for Anatomic Stage IV Breast Cancer AJCC v8. The current trial status is active. This product is registered under clinical trial identifier NCT04445844. Target conditions include Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04445844 | Phase 2 | Active |
Competing Products
13 competing products in Anatomic Stage IV Breast Cancer AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Niraparib Tosylate Monohydrate | Eli Lilly | Phase 1 | 33 |
| Capivasertib + Ceralasertib + Durvalumab + Olaparib + Selumetinib | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab + Tamoxifen + Vorinostat | Merck | Phase 2 | 52 |
| Carboplatin + Docetaxel + Fulvestrant + Pertuzumab + Ribociclib + Trastuzumab + Tucatinib | Novartis | Phase 1/2 | 41 |
| Lutetium Lu 177 Dotatate | Novartis | Phase 2 | 52 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Paclitaxel + Talimogene Laherparepvec + Tamoxifen + Nab paclitaxel + Gemcitabine + Carboplatin | Amgen | Phase 1 | 32 |
| Sacituzumab Govitecan | Gilead Sciences | Phase 2 | 51 |
| Anastrozole + Exemestane + Fulvestrant + Letrozole + Palbociclib + Tamoxifen | Pfizer | Phase 2 | 51 |
| Abexinostat Tosylate + Fulvestrant + Palbociclib | Pfizer | Phase 1 | 32 |
| Aromatase Inhibition Therapy | Bristol Myers Squibb | Pre-clinical | 22 |
| Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody | Imugene | Phase 1 | 25 |
| Neratinib | Puma Biotechnology | Phase 2 | 44 |
| Ivermectin + Balstilmab + Pembrolizumab | Agenus | Phase 1/2 | 33 |